MARKET

LGVN

LGVN

Longeveron Inc
NASDAQ
0.5401
+0.0271
+5.28%
After Hours: 0.5388 -0.0013 -0.24% 19:22 02/09 EST
OPEN
0.5050
PREV CLOSE
0.5130
HIGH
0.5519
LOW
0.5050
VOLUME
102.16K
TURNOVER
--
52 WEEK HIGH
1.920
52 WEEK LOW
0.4920
MARKET CAP
11.52M
P/E (TTM)
-0.4041
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LGVN last week (0202-0206)?
Weekly Report · 16h ago
Longeveron ‘applauds’ Mikaela Naylon Give Kids a Chance Act passage
TipRanks · 4d ago
Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program
Barchart · 4d ago
Weekly Report: what happened at LGVN last week (0126-0130)?
Weekly Report · 02/02 10:06
Longeveron granted Japan patent for potency assay methods for MSCs
TipRanks · 01/29 14:21
Longeveron Receives Patent From Japan Patent Office Covering Potency Assay Methods For Assessing Human Mesenchymal Stem Cells
Benzinga · 01/29 14:16
LONGEVERON® GRANTED JAPAN PATENT FOR POTENCY ASSAY METHODS FOR ASSESSING HUMAN MESENCHYMAL STEM CELLS (MSCS)
Reuters · 01/29 14:15
Longeveron granted FDA Type C Meeting ahead of ELPIS II data readout
TipRanks · 01/26 14:21
More
About LGVN
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.

Webull offers Longeveron Inc stock information, including NASDAQ: LGVN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LGVN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LGVN stock methods without spending real money on the virtual paper trading platform.